Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, phase II, open-label, non-randomized clinical trial designed to evaluate the safety and efficacy of the Fludarabine plus Treosulfan 14 g/m (FT14) conditioning regimen for allogeneic stem cell transplantation (allo-SCT) in patients with Acute Myeloid Leukemia (AML) aged 40-65 years who are in complete remission.
Phase:
PHASE2
Details
Lead Sponsor:
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia